NASDAQ: TCBPTc Biopharm PLC Stock
$1.57+0.10 (+6.8%)
Updated Apr 25, 2024
TCBP Price
$1.57
Fair Value Price
$2.68
Market Cap
$5.02M
52 Week Low
$0.85
52 Week High
$26.80
P/E
-0.06x
P/B
1.46x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$7.48M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
2.33
Operating Cash Flow
-$13M
Beta
1.57
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
TCBP Overview
TC Biopharm (Holdings) Plc is a clinical-stage biopharmaceutical company developing immunotherapy products based on its allogeneic gamma delta T cell platform. Its product pipeline includes OmnImmune, an unmodified cell therapy used in the treatment of acute myeloid leukemia, and ImmuniStim, an unmodified cell therapy to treat COVID-19. TC Biopharm was founded in 2013 and is headquartered in Motherwell, UK.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how TCBP scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
TCBP ($1.57) is undervalued by 41.36% relative to our estimate of its Fair Value price of $2.68 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
TCBP ($1.57) is significantly undervalued by 41.36% relative to our estimate of its Fair Value price of $2.68 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
TCBP is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more TCBP due diligence checks available for Premium users.
Be the first to know about important TCBP news, forecast changes, insider trades & much more!
TCBP News
Valuation
TCBP fair value
Fair Value of TCBP stock based on Discounted Cash Flow (DCF)
Price
$1.57
Fair Value
$2.68
Undervalued by
41.36%
TCBP ($1.57) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
TCBP ($1.57) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
TCBP is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
TCBP price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.06x
Industry
15.41x
Market
40.97x
TCBP price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.46x
Industry
5.8x
TCBP is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
TCBP's financial health
Profit margin
Revenue
$0.0
Net Income
$0.0
Profit Margin
0%
TCBP's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$11.3M
Liabilities
$7.9M
Debt to equity
2.33
TCBP's short-term assets ($7.31M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
TCBP's short-term assets ($7.31M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
TCBP's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
N/A
Investing
N/A
Financing
N/A
TCBP's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
TCBP vs Biotech Stocks
Tc Biopharm Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.